Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity. The study will evaluate GI toxicity, overall survival, local control, quality of life, and workflow metrics.

Trial Details

NCT ID
NCT05764720
Phase
NA
Sponsor
Varian, a Siemens Healthineers Company
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Daily Adaptive External Beam Radiation Therapy
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Cleveland, Ohio, United States|41.4995,-81.69541

Key Eligibility Criteria

  • Histologically or cytologically confirmed borderline-resectable (based on NCCN criteria), locally-advanced (based on NCCN criteria), or medically i…
  • ECOG performance status 0-1
  • Receipt of at least two months of lead-in chemotherapy (regimen at the discretion of the treating physician) prior to planned initiation of CT-STAR.
  • Limited regional lymphadenopathy permitted. Node positive patients are restricted to those with up to 3 clinically involved (greater than 1cm on cr…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →